Home sensor

MipSalus is committed to developing a home sensor allowing PKU patients to conveniently monitor the concentration of phenylalanine (Phe) in their blood. Daily Phe readings would enable patients to swiftly adjust medication and food intake resulting in significant health benefits.

Under current practice, PKU patients are offered a few Phe tests per months – with a higher frequency for children, pregnant women and KUVAN® patients. However, current practice is expensive and time-consuming: PKU clinics draw blood tests from patients and forward tests to laboratories for further analysis after which the laboratories return results to the PKU clinics who subsequently inform patients. MipSalus’ vision is to provide reliable Phe readings within minutes at home – to the benefits of patients, practitioners and ultimately the insurance companies and health authorities, carrying the associated costs.

The home sensor project is based on the MipSalus team’s year-long experience with receptor technologies combined with MipSalus’ MIPs’ technology.

A home sensor will be applicable for all kinds of treatment of HPA patients, both MipSalus’ upcoming treatment and the current treatment involving strict diet combined with protein substitute tablets as well as KUVAN® treatment.

New proprietary drug

MipSalus is developing a new proprietary drug – the first in a new class of medicines – for the treatment of all variants of HPA (Hyperphenylalaninemia)


The disease

Phenylketonuria (PKU) is a serious, congenital, lifelong metabolic disease caused by a defect in the phenylalanine hydroxylase (PAH) enzyme.